Davidson Kempner Capital Management LP Neurocrine Biosciences Inc Transaction History

Davidson Kempner Capital Management LP

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2017 Feb 14, 2018	SELL	$58.53 - $77.59 $2.29 Million - $3.03 Million	-39,100 Reduced 32.77%	80,200 $6.22 Million
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $5.72 Million - $7.31 Million	119,300	119,300 $7.31 Million

642

94.9M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $14.4B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Davidson Kempner Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Davidson Kempner Capital Management LP with notifications on news.